Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Theratechnologies ( (TSE:TH) ) just unveiled an announcement.
Theratechnologies Inc. has entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, for US$3.01 per share in cash and a contingent value right (CVR) for potential additional payments. This transaction, which represents a significant premium over the company’s previous stock price, is the result of a comprehensive sale process aimed at maximizing shareholder value. The acquisition is expected to enhance Future Pak’s growth strategy by expanding its product portfolio and improving patient access, marking a significant milestone in its history.
The most recent analyst rating on (TSE:TH) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on Theratechnologies stock, see the TSE:TH Stock Forecast page.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Despite strong revenue growth and recent FDA approvals, Theratechnologies faces significant challenges in profitability, financial stability, and short-term stock trends. These factors weigh heavily on the overall score.
To see Spark’s full report on TSE:TH stock, click here.
More about Theratechnologies
Theratechnologies Inc. is a commercial-stage biopharmaceutical company that focuses on developing and commercializing innovative medicines. The company operates in the pharmaceutical industry and is known for its contributions to patient care through its product portfolio.
Average Trading Volume: 117,460
Technical Sentiment Signal: Hold
Current Market Cap: C$149.4M
For detailed information about TH stock, go to TipRanks’ Stock Analysis page.